I am going to review the clinical practice guideline for the management of dyslipidemia and
prevention of cardiovascular disease that was developed by the American Association of Clinical
Endocrinologist and the Americ
...
I am going to review the clinical practice guideline for the management of dyslipidemia and
prevention of cardiovascular disease that was developed by the American Association of Clinical
Endocrinologist and the American College of Endocrinology.
Dyslipidemia is a broad term that refers to plasma that contains elevated levels of lipids.
It is also considered to be the primary risk factor for the development of cardiovascular disease.
This clinical practice guideline, or CPG, was developed to assist in screening, risk assessment
and treatment of patients with dyslipidemia with the ultimate goal being to reduce the risk of
cardiovascular disease and prevention of atherosclerosis.
First we are going to review some information starting with the epidemiology. According to the
CDC, in 2015 to 2016, 12.4 %, or 31 million adults in the US had a total cholesterol level over
240 mg/dL. This is a reduction from 18% which was present in the year 2000. Overall, this
meets the Healthy People 2020 goal for the prevalence of high total cholesterol to be less than
13.5%, however some groups still do not meet this goal. For example, in the 40-59 age group,
17% of men and 17.7% of women have elevated total cholesterol. There is also cultural
differences in prevalence with 43.1% of Hispanic men and 41.2% of Hispanic women with
having elevated total cholesterol levels.
Regarding the incidence of heart disease, it is estimated that every 40 seconds someone in the
U.S. has a heart attack, which equates to a reported incidence or 790,000 events per year.
Treatment of dyslipidemia, is considered the primary prevention for atherosclerosis.
Next we are going to review the pathophysiology. Atherosclerosis is defined as a buildup of
cholesterol laden plaque within arteries. The pathophysiology behind atherosclerosis is that it is
an inflammatory process that starts with injury to the inner lining of arterial walls due to risk
factors such as smoking or hypertension. This inflammation activates cytokines and allows LDL
to become deposited in the intimal layer of arteries and produce foam cells which is the basis of
atherosclerotic plaques. As the plaque builds up it can cause narrowing of arteries that occludes
blood flow.
One of the challenges with dyslipidemia is that patients are often asymptomatic until it has
progressed to the point where it has caused flow limiting atherosclerosis. At that point, the
patient could present with symptoms such as exertional chest pain, lower extremity claudication
as is seen in peripheral vascular disease, or TIA’s. Physical assessment findings that may be
present are arcus senilis, xanthelasma, or carotid bruits but these findings they may not be
present in every patient with dyslipidemia. In fact, most patients with dyslipidemia are
asymptomatic and that is why screening has such an important role in the treatment and
prevention of both dyslipidemia and cardiovascular disease.
This CPG was developed by the board of directors of the American Association of Clinical
Endocrinologists, or the AACE, and the Board of Trustees of the American College of
Endocrinology. The authors are all physicians who are members of the AACE, are credentialed
in endocrinology, and have attested that they do not have a financial association that is being
promoted with this CPG. The CPG was developed through initial review of current evidenced
based studies by the authors, and subsequent review by remaining members the CPG committee.
This study source was downloaded by 100000831988016 from CourseHero.com on 01-19-2022 13:21:50 GMT -06:00
https://www.coursehero.com/file/32999589/NR511-Dyslipidemia-CPG-transcriptdocx/
After the CPG was written, it was also reviewed by clinical experts and submitted for peer
review before final publication.
The initial AACE task force was created to create guidelines for the treatment of dyslipidemia
was initiated in 1999. This task force published the first clinical practice guideline in 2000 and
was revised in 2012, and has been revised a second time to reach its current form which was
published in 2017.
This CPG was written with the intent to be used not only by endocrinologists, but all healthcare
professionals to reduce cardiovascular risks associated with dyslipidemia. This is a valuable tool
for primary care as approximately 20% of all outpatient visits are associated with a diagnosis of
hyperlipidemia. Primary and secondary prevention of dyslipidemia in primary care can have a
significant impact on heart disease, which is the leading cause of death in the United States.
This CPG is very comprehensive and contains 87 recommendations to address a wide range of
patients, with each being graded on the care of dyslipidemia to prevent coronary artery disease.
In this CPG, two grading scales were applied to each recommendation. The first is a 4 level
scale addressing the recommendation grade with an A grade meaning there is a strong
recommendation, down to a Level D which is given when there is no conclusive evidence or
only expert opinion available.
The second scale is also a 4 level scale that addresses that best evidence level, or BEL, based on
the quality or level of supporting evidence for the recommendation. With this scale, a BEL of
one is the highest rating, which indicates a strong level of supporting evidence, and a BEL of 4
indicates no supporting evidence is available. Each recommendation in this CPG was given both
a Recommendation Grade and a Best Evidence Level. For this presentation, only 5
recommendations that were applicable to a sample patient seen in the primary care will be
presented.
First lets discuss who should be screened for dyslipidemia. This CPG recommends that men
between the ages of 20 to 45 should be evaluated every 5 years. This information can then be
applied to their 10 year risk of atherosclerotic heart disease which we will talk about more about
in an upcoming slide. The evidence grading for this recommendation is Grade C, or weak
grading, and BEL or best evidence level of 4 primarily based on cost effectiveness. This CPG is
very applicable for use in primary care by making recommendations for screening of specific age
groups and comorbidities. This next slide is a summary of some of these recommendations and
how often they should be screened based on age and comorbidity status.
This CPG recommends the use of a fasting lipid profile as the primary test or tool to evaluate for
total cholesterol, LDL level, HDL level and triglycerides as indicators of dyslipidemia. The
evidence grading for this recommendation is also a grade C and a BEL of 4. Patients that need to
have lipid lab work should be instructed to either arrive at their appointment in a fasting state, or
have fasting labs done prior to appointment to allow for review of labs during appointment.
Treatment goals
[Show More]